Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.63 |
| ▸ | JAK2 | O60674 | 3/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898695 | 0.89 | JAK2 (0.78) | IKBKBJAK2JAK3 | |
| SCHEMBL7052455 | 0.87 | IKBKB (0.60) | IKBKBJAK2JAK3CHEK1 | |
| SCHEMBL5898648 | 0.86 | JAK2 (0.64) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL5898656 | 0.86 | JAK2 (0.64) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL5898690 | 0.86 | JAK2 (0.61) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL5898692 | 0.84 | JAK2 (0.59) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL5898672 | 0.84 | IKBKB (0.59) | IKBKBJAK2JAK3CHEK1 | |
| SCHEMBL5898639 | 0.84 | JAK2 (0.65) | IKBKBJAK2JAK3MEN1EIF2AK2 | |
| SCHEMBL5898674 | 0.84 | IKBKB (0.59) | IKBKBJAK2JAK3CHEK1 | |
| SCHEMBL5898678 | 0.83 | JAK2 (0.57) | IKBKBJAK2JAK3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030596-A1 | NF-kappaB inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-02-09 | — | — | US | disclosed |
| EP-1324759-A4 | NF-G(K)B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040024047-A1 | Nf-kb inhibitors | SMITHKLINE BEECHMAN CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1324759-A2 | NF-G(K)B INHIBITORS | SmithKline Beecham Corporation (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030353-A2 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030596-A1 | NF-kappaB inhibitors | NFKBIA, IKBKB, IKBKG | IKBKB 2/4885JAK2 171/4885JAK3 275/4885 |
| US-20040024047-A1 | Nf-kb inhibitors | NFKBIA, IKBKB, IKBKG | IKBKB 2/4885JAK2 308/4885JAK3 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.